Description
Klow Blend (GHK-Cu + BPC-157 + TB-500 + KPV) | 80 mg
BioChain USA · Research use only
What Is the Klow Blend?
This product is a four-peptide research formulation containing GHK-Cu (50 mg), BPC-157 (10 mg), TB-500 (10 mg), and KPV (10 mg), supplied as a single lyophilized 80 mg vial. Each of the four compounds is an independently characterized peptide or peptide-copper complex with its own published research literature.
The Klow Blend brings them together in a single preparation for research contexts where investigators study the effects of co-administering compounds with overlapping or complementary research mechanisms in tissue-repair, inflammation, and regenerative biology model systems.
The four components span three published research domains: extracellular matrix / wound healing biology (GHK-Cu), gut and vascular signaling biology (BPC-157), actin cytoskeletal and angiogenic biology (TB-500), and α-MSH-derived anti-inflammatory signaling (KPV). No peer-reviewed published research has evaluated the four-component Klow formulation as a whole; the literature consists of independent research on each component.
BioChain USA does not represent component-level findings as outcomes for the blended formulation.
Klow Blend (GHK-Cu + BPC-157 + TB-500 + KPV) in Plain Language
A non-technical overview of what this four-peptide blend is, what researchers have studied each component for, what early evidence suggests, and what cannot be claimed about it. For research and educational purposes only.
At a glance
The Klow Blend combines four research peptides, the same three found in the Glow Blend (GHK-Cu, BPC-157, TB-500) plus KPV, a small anti-inflammatory peptide. Researchers study the combination in laboratory models for situations where tissue repair and inflammation control are both important at the same time, for example, slow-healing wounds, stubborn skin conditions, or surgical sites with heavy inflammation.
The blend sold here is a research chemical preparation, not a cosmetic or therapeutic product.
What it is
The Klow Blend is a research preparation combining four peptides that have each been studied independently in published tissue-repair and inflammation literature. It can be thought of as the Glow Blend (GHK-Cu + BPC-157 + TB-500) with the addition of KPV, an anti-inflammatory tripeptide derived from the C-terminus of α-MSH:
- GHK-Cu. The copper(II) complex of the natural human tripeptide glycyl-L-histidyl-L-lysine. Studied in research on extracellular matrix biology, collagen and glycosaminoglycan synthesis in fibroblasts, wound-healing models, copper-dependent enzyme cofactor research, and gene-expression effects.
- BPC-157. A synthetic 15-amino-acid peptide (Body Protection Compound 157, also known in the clinical-trial literature as PL-14736) based on a partial sequence of a larger protein originally identified in human gastric juice. Studied in research on tissue-repair signaling, nitric-oxide / angiogenesis pathways, gastrointestinal lining biology, and tendon and ligament injury models.
- TB-500. A synthetic 43-amino-acid peptide identical in sequence to thymosin beta-4 (Tβ4), an actin-binding protein found inside most mammalian cells. Studied in research on cell migration, wound-healing models, blood-vessel formation, and cardiac tissue repair models.
- KPV. A synthetic tripeptide (lysine-proline-valine) corresponding to the last three amino acids of α-melanocyte-stimulating hormone (α-MSH). Studied in research on inflammation pathways (NF-κB, p38 MAPK), pro-inflammatory cytokine biology, gut inflammation models, and the PepT1 (SLC15A1) di/tripeptide transporter.
Researchers studying tissue-repair and inflammation biology occasionally combine these peptides because their published mechanistic frameworks, collagen / matrix biology (GHK-Cu), angiogenic and gut-mucosal signaling (BPC-157), actin-cytoskeletal and cell-migration biology (TB-500), and direct anti-inflammatory NF-κB / MAPK signaling (KPV), are non-overlapping but converge on shared research endpoints in tissue-repair and inflammation model systems.
Research areas being investigated
- Extracellular matrix research: GHK-Cu in fibroblast cultures for collagen and proteoglycan synthesis.
- Wound-healing research: All four peptides in animal models of skin and connective-tissue repair, with KPV adding an inflammation-focused arm.
- Vascular / angiogenesis research: BPC-157 and TB-500 for endothelial behavior and capillary-formation endpoints.
- Cell-migration research: TB-500 for actin-binding effects on cell migration.
- Inflammation research: KPV for NF-κB and p38 MAPK suppression and cytokine reduction (TNF-α, IL-6, IL-8); all four peptides in cytokine-focused experiments.
- Gastrointestinal research: BPC-157 in stomach and gut-barrier injury models; KPV in DSS- and TNBS-induced colitis models in rodents.
- PepT1 transporter research: KPV is studied as a substrate of the PepT1 di/tripeptide transporter, which is upregulated in inflamed gut tissue.
What the research suggests so far
Animal / preclinical findings. Most published evidence on each peptide comes from rodent and cell-culture studies. Researchers have reported observations consistent with faster wound closure in skin models (GHK-Cu), faster healing in models of skin wounds, gastric ulcers, colitis, and tendon detachment (BPC-157), faster cellular migration with more capillary-tube formation in angiogenesis assays (TB-500), and reduced disease-activity scores with lower colonic pro-inflammatory cytokine expression in colitis models (KPV).
These findings do not, on their own, demonstrate the same effects in humans, and combined-blend research is sparser than research on each peptide individually.
Cell / lab findings. Cell-culture work has characterized GHK-Cu’s collagen / glycosaminoglycan stimulation; BPC-157’s effects on eNOS and VEGFR2; TB-500’s G-actin binding; and KPV’s NF-κB and p38 MAPK suppression at nanomolar concentrations, alongside its uptake via PepT1. These mechanistic findings are several steps removed from clinical outcomes.
Human findings. Human evidence for each peptide is limited. GHK-Cu has appeared in small cosmetic-formulation studies (typically as a topical cream). The most cited human work for BPC-157 is an early-phase clinical program under the development name PL-14736 for inflammatory bowel disease. For TB-500, the most cited human work involves topical and ophthalmic Tβ4 formulations (e.g., RGN-259) studied in early-phase trials.
KPV itself has very limited direct human evidence. There are no large, published Phase III randomized controlled trials demonstrating efficacy for any condition for any of the four peptides. None is approved by the FDA, EMA, or other major regulators as a drug for any use.
Limitations of the evidence. The literature for each peptide is dominated by cell-culture and small-animal work. Long-term human safety data, large-scale efficacy trials, and standardized human dosing studies are lacking.
Combined-blend research (versus each peptide individually) is comparatively limited, so most claims about “synergy” among the four are extrapolation rather than strong empirical support. Reviewers in the recent peer-reviewed literature have specifically called out the need for additional rigorous human studies before any therapeutic conclusions can be drawn.
Research relevance
The Klow Blend is most often discussed in research involving extracellular matrix biology and collagen production (GHK-Cu lineage), tissue-repair signaling and nitric-oxide / angiogenic pathways (BPC-157 lineage), actin cytoskeletal dynamics and cell migration (TB-500 lineage), and direct anti-inflammatory signaling via NF-κB and MAPK pathways (KPV lineage). It overlaps with skin-biology, wound-healing, gut-inflammation, and dermatology research.
Most published findings are preclinical, so it should not be presented as a proven treatment for any condition. Its scientific interest lies in its potential use as a research tool for studying the intersection of tissue-repair and inflammation biology in the laboratory.
What cannot be claimed about the Klow Blend
- It cannot be claimed to treat, cure, heal, or prevent any human or animal condition.
- It cannot be claimed to reverse aging, eliminate wrinkles, regrow hair, or restore skin elasticity in humans.
- It cannot be claimed to heal wounds, scars, burns, or surgical injuries in humans or veterinary patients.
- It cannot be claimed to treat inflammatory bowel disease, ulcerative colitis, Crohn’s disease, or leaky gut in humans.
- It cannot be claimed to treat acne, eczema, psoriasis, rosacea, or any inflammatory skin condition.
- It cannot be claimed to be safe or effective for human or veterinary use.
- It cannot be claimed to be approved by the FDA or any other regulatory authority as a drug.
- It cannot be represented as a cosmetic, dietary supplement, or topical product.
Summary
The Klow Blend is a research preparation combining GHK-Cu (the copper complex of the natural human tripeptide GHK), BPC-157 (a synthetic 15-amino-acid peptide from human gastric juice protein), TB-500 (a synthetic 43-amino-acid peptide identical to thymosin beta-4), and KPV (a synthetic tripeptide from the C-terminus of α-MSH). It is studied in laboratory and animal research on extracellular matrix biology, tissue-repair signaling, vascular and angiogenic biology, cell-migration biology, and inflammation pathways including NF-κB and MAPK signaling.
Published evidence comes mainly from cell-culture and rodent experiments; human evidence for each peptide is limited. None is approved by the FDA or any other regulator as a drug.
BioChain USA’s preparation is sold strictly as a research-use-only chemical for laboratory investigation. It is not intended for human consumption, cosmetic use, medical use, or veterinary use.
Short version
The Klow Blend combines GHK-Cu, BPC-157, TB-500, and KPV. All four are studied in preclinical research on tissue repair and inflammation. None is approved by the FDA as a drug. Sold for research and laboratory use only.
Source notes
- Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in light of the new gene data. Int J Mol Sci, 2018, review article. (PMC6073405.)
- Sikiric P. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des, 2011, review article. (PubMed PMID: 21548867.)
- Goldstein AL, Hannappel E, Kleinman HK. Thymosin β4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med, 2005, review article.
- Brzoska T, et al. Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, anti-inflammatory and protective effects in vitro and in vivo. Endocr Rev, 2008, review article. (PMC2095288.)
- Dalmasso G, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology, 2008, animal/cell study. (PMC2431115.)
- Deek SA, et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. 2024, peer-reviewed narrative review. (PMC12446177.)
Source types: entries 1, 2, 3, 4, 6 are review articles synthesizing the preclinical literature for each constituent peptide; entry 5 is an animal / cell-culture study.
SEO meta description
Klow Blend (GHK-Cu + BPC-157 + TB-500 + KPV, research-grade) combines four peptides studied in preclinical research on tissue repair and inflammation. Research-use only.
Reminder. BioChain USA sells the Klow Blend strictly as a research-use-only chemical for qualified laboratory and educational use. None of its component peptides is FDA-approved, and this product is not intended for human consumption, cosmetic use, medical treatment, veterinary treatment, diagnosis, prevention, or cure of disease.
Chemical Reference Data
GHK-Cu (Copper Tripeptide-1), 50 mg
| Sequence | Gly-His-Lys · Cu²⁺ |
|---|---|
| Molecular Formula | C₁₆H₂₈CuN₆O₆ |
| Molecular Weight | ~463.98 g/mol |
| Peptide Length | 3 amino acids |
| Structural Class | Copper(II) coordination complex of glycyl-L-histidyl-L-lysine |
| CAS (complex) | 89030-95-5 |
| CAS (free GHK) | 49557-75-7 |
BPC-157 (Body Protection Compound 157), 10 mg
| Molecular Formula | C₆₂H₉₈N₁₆O₂₂ |
|---|---|
| Molecular Weight | ~1,419.6 g/mol |
| Peptide Length | 15 amino acids |
| Structural Class | Synthetic pentadecapeptide derived from human gastric protein sequence |
| CAS Number | 137525-51-0 |
TB-500 (Thymosin Beta-4 Synthetic), 10 mg
| Molecular Formula | C₂₁₂H₃₅₀N₅₆O₇₈S |
|---|---|
| Molecular Weight | ~4,963.5 g/mol |
| Peptide Length | 43 amino acids |
| Structural Class | Synthetic linear polypeptide corresponding to thymosin beta-4 (Tβ4) sequence |
| CAS Number | 77591-33-4 |
KPV (α-MSH 11-13 Tripeptide), 10 mg
| Sequence | Lys-Pro-Val |
|---|---|
| Molecular Formula | C₁₆H₃₀N₄O₄ (free acid form) |
| Molecular Weight | ~342.43 g/mol |
| Peptide Length | 3 amino acids |
| Structural Class | C-terminal tripeptide fragment of α-melanocyte stimulating hormone (α-MSH 11-13) |
Composition and Formulation
This blend is supplied as a single lyophilized cake of four research compounds, no fillers, excipients, or carriers beyond what is required for lyophilization. The four components are chemically distinct: three peptides (BPC-157, TB-500, KPV) and one peptide-copper coordination complex (GHK-Cu).
Their molecular weights span an order of magnitude from KPV (~342 g/mol) to TB-500 (~4,963 g/mol), and their amino-acid compositions do not overlap, so each component remains chemically distinguishable in a co-formulated preparation.
The mass ratio (50:10:10:10) reflects the typical industry convention for this 4-peptide combination. Researchers reconstituting the blend in laboratory-grade solvent should reference batch COA documentation for combined-preparation testing data.
BioChain USA does not make medical claims. Research context does not equal clinical outcome data.
Research Applications
This blend is used as a research tool to investigate, by component:
- GHK-Cu, Extracellular matrix biology, collagen / glycosaminoglycan synthesis, lysyl oxidase / hydroxylase cofactor research, wound-repair model systems, DNA repair gene expression
- BPC-157, Nitric oxide pathway modulation, VEGF-related angiogenic signaling, gut and mucosal barrier biology, growth hormone receptor interactions
- TB-500, G-actin / F-actin equilibrium, cell migration in wound and tissue remodeling models, vessel formation in cardiac and vascular research, anti-inflammatory signaling contexts
- KPV, NF-κB and MAPK pathway inhibition, PepT1 transporter biology, intestinal inflammation models, α-MSH structure-activity research
- Combined co-administration research design, investigation of complementary or additive mechanisms across extracellular matrix, vascular, and inflammatory signaling pathways in preclinical tissue-repair model systems
Specific applications depend on the researcher’s study design, cell model, and assay framework.
Key Research Themes in the Literature
1. Extracellular Matrix and Wound Repair (GHK-Cu)
Published research describes GHK-Cu as a stimulator of collagen and glycosaminoglycan synthesis in dermal fibroblast culture systems, with the copper component serving as an obligatory cofactor for lysyl oxidase and lysyl hydroxylase enzymes responsible for collagen cross-linking. GHK-Cu is broadly studied in published preclinical wound-healing literature including ischemic, diabetic, and connective-tissue model systems.
Connectivity Map analyses have additionally reported broad upregulation of DNA repair pathway gene expression in response to GHK in cell culture.
2. Vascular and Mucosal Signaling (BPC-157)
BPC-157 is examined in published literature in relation to nitric oxide pathway regulation, including interactions with endothelial nitric oxide synthase (eNOS) signaling and downstream vascular biology effects in experimental systems. Additional published research themes include VEGF-pathway angiogenic signaling in in vitro assay frameworks, gastrointestinal mucosal barrier biology, and growth hormone receptor expression / sensitization in specific preclinical model contexts.
3. Actin Cytoskeletal Dynamics and Angiogenesis (TB-500 / Tβ4)
TB-500 corresponds in sequence to thymosin beta-4 (Tβ4), described in published biochemistry literature as the primary G-actin sequestering protein in mammalian cells. Published research examines actin monomer sequestration (binding G-actin at approximately 1:1 molar ratio), cell migration and motility in wound healing model systems, cytoskeletal remodeling, and angiogenesis-related signaling in cardiac and vascular research contexts.
4. NF-κB / MAPK Inhibition and PepT1 Transport (KPV)
KPV is examined in published literature as a small fragment of α-MSH that retains anti-inflammatory activity without melanocortin receptor engagement. Reported mechanisms include inhibition of NF-κB nuclear translocation (suppressing TNF-α, IL-6, IL-8 transcription) and suppression of p38 / MAPK phosphorylation cascades at nanomolar concentrations.
KPV is also examined as a substrate of the PepT1 (SLC15A1) di/tripeptide transporter, providing a self-targeting uptake mechanism in inflamed intestinal epithelium in published preclinical research.
5. Co-Administration Research Design Context
The four components are frequently discussed together in industry and applied research contexts as complementary based on their respective, and partially overlapping, mechanisms across vascular, extracellular matrix, and anti-inflammatory signaling. No peer-reviewed published research has evaluated the four-component Klow formulation as a whole; the existing literature consists of independent component-level research.
Researchers using this blend should design experiments around component-level mechanistic hypotheses rather than blend-level claims. BioChain USA does not represent the combination of these four compounds as having been validated in peer-reviewed combined-administration research.
Certificate of Analysis (COA)
- COA provided where available for the specific batch shipped.
- The batch COA is the authoritative reference for analytical methods, purity data, and lot-specific testing for that shipment.
- COA information is batch-specific and is not interchangeable between lots.
- For blend products, COA documentation reflects testing of the combined preparation as shipped.
Storage and Handling
General peptide handling guidance for research use:
- Store in a cool, dry, dark environment.
- For extended storage, follow standard peptide handling protocols: cold storage with protection from light and moisture.
- Avoid repeated open-close cycles that introduce humidity to the lyophilized material.
- If preparing solutions for laboratory use, standard guidance recommends avoiding long-term storage in reconstituted form, aliquot as appropriate for the experimental design.
BioChain USA does not provide instructions for human or animal administration.
Frequently Asked Questions
Is this product for human use?
No. This blend is not approved or intended for human or veterinary use. It is sold exclusively for in vitro research, laboratory, and analytical purposes. It is not a drug, supplement, or therapeutic product of any kind.
What is the Klow Blend used for in research?
The Klow Blend is studied as a co-administration research formulation combining four independently characterized compounds: GHK-Cu (extracellular matrix and wound repair biology), BPC-157 (nitric oxide / VEGF / gut signaling), TB-500 (actin cytoskeletal dynamics and angiogenesis), and KPV (NF-κB / MAPK inhibition and PepT1 transport). Researchers use this combined preparation to examine complementary or additive effects across vascular, matrix, and inflammatory signaling pathways in preclinical tissue-repair model systems.
No peer-reviewed published research has evaluated the four-component formulation as a whole, applications are component-mechanism driven. Specific applications depend on the researcher’s study design and objectives.
Do you provide dosing instructions or administration protocols?
No. BioChain USA does not provide dosing guidance, administration instructions, or protocols for human or animal use. Researchers are responsible for designing in vitro study protocols appropriate to their applications and institutional requirements.
Do you provide a Certificate of Analysis (COA)?
Yes, where available. COAs are batch-specific documents reflecting the analytical testing and purity data for that particular lot. The COA included with your order is the authoritative reference for that batch. For blend products, COA documentation reflects testing of the combined preparation as shipped. Availability may vary by lot.
Compliance and Disclaimers
- Sold for research, laboratory, or analytical purposes only.
- Not intended to diagnose, treat, cure, or prevent any disease or condition.
- Not for human or animal consumption.
- Purchaser assumes full responsibility for compliance with all applicable local, state, and federal regulations governing the purchase and use of research compounds.
References & additional KLOW resources
KLOW Overview at BioChain USA
This KLOW product page lists the 80 mg lyophilized vial of the BioChain USA research-grade KLOW compound.
Every KLOW lot is independently third-party tested, with a COA available per batch.
KLOW is supplied strictly for in vitro research use and is not approved for human or animal consumption.
KLOW Product Imagery
Related BioChain Research Peptides
KLOW is part of a broader catalog of research-grade peptides at BioChain USA. Each related product is third-party tested.
- GHK-Cu research-grade peptide
- BPC-157 research-grade peptide
- TB-500 research-grade peptide
- KPV research-grade peptide
External Peer-Reviewed Research Literature
Investigators studying the KLOW compound class may consult external research databases for published literature.
- PubMed: KLOW published research literature
- NCBI PMC: KLOW open access articles
- PubMed: peptide research literature
KLOW FAQ
What is KLOW? KLOW is a research-grade compound supplied by BioChain USA as a lyophilized vial for in vitro laboratory research only.
What vial size does BioChain USA offer? This product page lists the 80 mg vial size.
Is KLOW tested? Yes. Every KLOW lot is independently third-party tested and ships with a COA reference when available.
Can KLOW be used on humans or animals? No. KLOW is supplied strictly for in vitro research use. It is not approved for human or animal consumption.
How does KLOW ship? BioChain USA ships KLOW as a lyophilized powder in a sealed research vial.
Where can researchers find KLOW published literature? PubMed and NCBI PMC list peer-reviewed studies on the KLOW compound class.
